Precision BioSciences Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) Transcript
Okay. Welcome, everyone, to our next session. My name is Ben Burnett with Stifel research, and I'm pleased to be here with Precision BioSciences. We have a couple of members of the team: Michael Amoroso, CEO; also joined by Jeff Smith, Co-Founder and Chief Research Officer; and Cassie Gorsuch, VP of Gene Therapy. So thank you all for being here.
Thank you for having us, Ben.
I think -- excellent. Like always, if you have any questions, submit them through -- there should be a chat feature or just shoot me an e-mail at [email protected]. I think in terms of the layout, we're going to keep it focused on the gene-editing program that you guys have an update very soon on the cell therapy. So this will be largely focused on the gene therapy gene-editing aspects.
But I would start with actually just the technology itself, where it came from, and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |